300233.SHE Shandong Jincheng Pharmaceutical and Chemical Co Ltd
- Market cap
- CNY 4.40B
- P/E
- 26.6x
- P/B
- 1.14x
- ROE
- 5.1%
- Dividend yield
- 3.70%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300233.SHE undervalued?
Graham number300233.SHE trades 16.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Jincheng Pharmaceutical and Chemical Co Ltd fundamental analysis
No fundamental analysis for Shandong Jincheng Pharmaceutical and Chemical Co Ltd yet.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin pharmaceutical intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. The company was founded in 2004 and is based in Zibo, China.
Full company profileShandong Jincheng Pharmaceutical and Chemical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.42B | 2.79B | 3.01B | 2.79B | 2.96B | 3.14B | 3.51B | 3.54B | 3.37B | 2.74B | 2.71B |
| Gross Profit | 395M | 992M | 1.48B | 1.60B | 1.69B | 1.60B | 1.57B | 1.46B | 1.30B | 986M | 928M |
| Operating Income | 153M | 340M | 368M | 155M | -415M | 210M | 354M | 226M | 267M | 137M | 225M |
| EBITDA | 271M | 505M | 555M | 514M | -204M | 443M | 625M | 557M | 605M | 410M | 249M |
| Net Income | 159M | 286M | 264M | 203M | -489M | 108M | 273M | 175M | 197M | 44.2M | 193M |
| EPS | 0.63 | 0.77 | 0.67 | 0.52 | -1.26 | 0.28 | 0.71 | 0.45 | 0.52 | 0.12 | 0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 2.26B | 4.90B | 5.29B | 5.59B | 5.00B | 5.28B | 5.83B | 5.92B | 5.60B | 5.19B | 5.00B |
| Total Liabilities | 753M | 966M | 1.20B | 1.51B | 1.53B | 1.84B | 2.17B | 2.14B | 1.77B | 1.47B | 1.18B |
| Shareholders' Equity | 1.44B | 3.86B | 4.01B | 4.06B | 3.44B | 3.39B | 3.61B | 3.71B | 3.77B | 3.66B | 3.75B |
| Cash & Short-term Investments | 446M | 683M | 722M | 990M | 1.07B | 981M | 859M | 1.02B | 918M | 826M | 783M |
| Total Debt | 268M | 284M | 517M | 621M | 473M | 653M | 651M | 444M | 414M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 241M | 152M | 352M | 578M | 546M | 437M | 256M | 664M | 297M | 320M | - |
| Capital Expenditure | 159M | 194M | 350M | 362M | 272M | 376M | 374M | 343M | 143M | 101M | 85.2M |
| Free Cash Flow | 82.6M | -42.0M | 2.32M | 216M | 274M | 61.0M | -118M | 321M | 154M | 219M | 275M |
| Ratios | |||||||||||
| ROE | 11.1% | 7.4% | 6.6% | 5.0% | -14.2% | 3.2% | 7.6% | 4.7% | 5.2% | 1.2% | 5.1% |
| ROA | 7.1% | 5.8% | 5.0% | 3.6% | -9.8% | 2.0% | 4.7% | 3.0% | 3.5% | 0.9% | 3.9% |
| Net Profit Margin | 11.2% | 10.3% | 8.8% | 7.3% | -16.5% | 3.4% | 7.8% | 4.9% | 5.8% | 1.6% | 7.1% |
| Debt to Equity | 0.19x | 0.07x | 0.13x | 0.15x | 0.14x | 0.19x | 0.18x | 0.12x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd dividends
- Dividend yield
- 3.70%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 367.8%
- Ex-dividend date
- May 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 163M | 0.42 | 367.8% |
| 2024 | CNY 132M | 0.35 | 66.9% |
| 2023 | CNY 83.5M | 0.22 | 47.8% |
| 2022 | CNY 76.5M | 0.20 | 28.0% |
| 2021 | CNY 77.5M | 0.20 | 71.8% |
| 2020 | CNY 77.7M | 0.20 | - |
| 2019 | CNY 97.6M | 0.25 | 48.0% |
| 2018 | CNY 94.7M | 0.24 | 35.9% |
| 2017 | CNY 70.8M | 0.19 | 24.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Sep 17, 2015.
Who owns Shandong Jincheng Pharmaceutical and Chemical Co Ltd
- Insiders 27.59%
- Institutions 3.61%
- Public & others 68.80%
- Shares outstanding 384M
- Free float 273M
Shandong Jincheng Pharmaceutical and Chemical Co Ltd company profile
- Company name
- Shandong Jincheng Pharmaceutical and Chemical Co Ltd
- Ticker
- 300233.SHE
- ISIN
- CNE100001500
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 22, 2011
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 3,515
- Fiscal year end
- December
- Address
- No.1 Shuangshan Road, Zibo, China, 255188
- Phone
- 86 53 3541 4988
- Website
- jinchengpharm.com
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin pharmaceutical intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. The company was founded in 2004 and is based in Zibo, China.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd management
6- Mr. Jiaquan LiPresident & Chairman · born 1972
- Ms. Jing LiuFinancial Director · born 1976
- Mr. Xi Li Cui CPAVP & Director · born 1973
- Mr. Zhongzheng ZhangVP & Director · born 1982
- Mr. Hui WangVP & Director · born 1983
- Mr. Xi Cheng ZhangVice President · born 1970